Is SOLTF or JEPQ a better dividend investment in 2026?

SOLTF currently yields 37.88% with a 5% 5-year dividend growth rate. JEPQ yields 11.10% with 5% growth. The better choice depends on your goal: SOLTF offers higher current income.

What is the dividend yield difference between SOLTF and JEPQ?

SOLTF has a forward dividend yield of 37.88% ($2.00/share annually). JEPQ yields 11.10% ($6.16/share annually). The yield gap is 26.78 percentage points.

Home › Compare › SOLTF vs JEPQ

SOLTF vs JEPQ: Dividend Comparison 2026

SOLTF yields 37.88% · JEPQ yields 11.10%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 SOLTF wins by $161.6K in total portfolio value

INVESTMENT

TIME HORIZON10 years

SOLTF

● Live price

37.88%

Share price

$5.28

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$206.4K

Annual income

$33,329.74

Full SOLTF calculator →

JEPQ

JPMorgan Nasdaq Equity Premium Income ETF

● Live price

11.10%

Share price

$55.52

Annual div

$6.16

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$44.8K

Annual income

$2,152.59

Full JEPQ calculator →

Portfolio growth — SOLTF vs JEPQ

📍 SOLTF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	SOLTF	JEPQ
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, SOLTF + JEPQ cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

SOLTF pays

JEPQ pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SOLTF

Annual income on $10K today (after 15% tax)

$3,219.70/yr

After 10yr DRIP, annual income (after tax)

$28,330.28/yr

JEPQ

Annual income on $10K today (after 15% tax)

$943.83/yr

After 10yr DRIP, annual income (after tax)

$1,829.70/yr

At 15% tax rate, SOLTF beats the other by $26,500.58/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SOLTF + JEPQ for your $10,000?

SOLTF: 50%JEPQ: 50%

100% JEPQ50/50100% SOLTF

Portfolio after 10yr

$125.6K

Annual income

$17,741.16/yr

Blended yield

14.12%

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SOLTF buys

JEPQ buys

No recent congressional trades found for SOLTF or JEPQ in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricSOLTFJEPQ

Forward yield	37.88% ✓	11.10%
Annual dividend / share	$2.00	$6.16 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	0%
Portfolio after 10y	$206.4K ✓	$44.8K
Annual income after 10y	$33,329.74 ✓	$2,152.59
Total dividends collected	$152.8K ✓	$16.3K
Payment frequency	quarterly	monthly
Sector	Stock	ETF

Year-by-year: SOLTF vs JEPQ ($10,000, DRIP)

Year	SOLTF Portfolio	SOLTF Income/yr	JEPQ Portfolio	JEPQ Income/yr	Gap
1← crossover	$14,488	$3,787.88	$11,930	$1,110.39	+$2.6K → SOLTF
2	$20,631	$5,128.82	$14,133	$1,224.34	+$6.5K → SOLTF
3	$28,901	$6,825.67	$16,632	$1,340.46	+$12.3K → SOLTF
4	$39,860	$8,936.20	$19,454	$1,457.97	+$20.4K → SOLTF
5	$54,169	$11,518.54	$22,626	$1,576.08	+$31.5K → SOLTF
6	$72,590	$14,629.36	$26,175	$1,694.09	+$46.4K → SOLTF
7	$95,993	$18,321.84	$30,133	$1,811.32	+$65.9K → SOLTF
8	$125,356	$22,643.78	$34,531	$1,927.17	+$90.8K → SOLTF
9	$161,767	$27,635.79	$39,403	$2,041.08	+$122.4K → SOLTF
10	$206,420	$33,329.74	$44,787	$2,152.59	+$161.6K → SOLTF

SOLTF vs JEPQ: Complete Analysis 2026

SOLTF — Stock

Nxera Pharma Co., Ltd. develops and sells biopharmaceutical products in Japan, Switzerland, the United States, Bermuda, and the United Kingdom. Its product portfolio products include Ultibro/Breezhaler and Seebri/Breezhaler for the treatment of chronic obstructive pulmonary disease; Enerzair and Breezhaler for the treatment of asthma; ORAVI, a novel formulation for the treatment of oropharyngeal candidiasis; and PIVLAZ for the treatment of cerebral vasospasm indications. The company's development products pipeline consists of HTL0039732 for immuno-oncology indications; HTL0048149 for schizophrenia disorders; Daridorexant for the treatment of insomnia; HTL0016878 for schizophrenia and other neuropsychiatric disorders; PF-07081532 for Type 2 diabetes mellitus and obesity; PF-07054894 for inflammatory bowel disease; PF-07258669 for anorexia; PF-06954522 for metabolic diseases; NBI-1117569 for neurology diseases; and NBI-1117570 for central nervous system (CNS) disorders. It is also involved in the development of GPR35 agonist, for inflammatory bowel disease/GI disorders, which is in preclinical stage; and other discovery and preclinical stage drugs. Nxera Pharma Co., Ltd. has a strategic collaboration with AbbVie, Biohaven, Genentech Inc., GSK, Pfizer Inc., Neurocrine Biosciences Inc., Novartis International AG, and Verily. Nxera Pharma Co., Ltd. was incorporated in 1990 and is headquartered in Tokyo, Japan.

Full SOLTF Calculator →

JEPQ — ETF

The fund seeks to achieve this objective by (1) creating an actively managed portfolio of equity securities comprised significantly of those included in the fund’s primary benchmark, the Nasdaq-100 Index (the Benchmark), and (2) through equity-linked notes (ELNs), selling call options with exposure to the Benchmark. It is non-diversified.

Full JEPQ Calculator →

📬

Get this SOLTF vs JEPQ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SOLTF vs SCHD SOLTF vs JEPI SOLTF vs O SOLTF vs KO SOLTF vs MAIN SOLTF vs XYLD SOLTF vs QYLD SOLTF vs VYM

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.